Photo detail

Stories this photo appears in:

FDA Gives Kite Cellular Drug Therapy Fast Track Designation

The FDA must decide within six months whether to approve the drug, known as KTE-X19

Tease photo

Key Deals: Kite Pharma Acquired by Gilead Sciences for $12 Billion

MONEY/Investment Banks

Gilead Sciences Inc.’s acquisition of Kite Pharma Inc. of Santa Monica for $12 billion was the headline-grabbing deal for the Los Angeles County biotech industry in 2017.

Tease photo